The Earlier the Better Early Response to Imatinib Predicted Outcomes in Children with CML

While imatinib has been proven effective for the majority of pediatric patients with chronic myeloid leukemia (CML), 13 to 25 percent of children still...

Moderate-Dose Cyclophosphamide for Severe Aplastic Anemia:Potential Toxicity Outweighs Potential Benefit

While cyclophosphamide at high or more moderate doses can be active in severe aplastic anemia, a new study published in Blood reveals that a...

New Target Holds Potential for Treatment of Common Anemia

Lexaptepid, an anti-hepcidin therapy, may be the first viable treatment option for patients with anemia of inflammation, according to the results of an experimental...

Good, But Not Optimal – HSCT Match Possible for Most Patients

For patients with certain blood cancers or other diseases, hematopoietic stem cell transplants (HSCT) are potentially lifesaving therapies. While the majority of patients are...

Ruxolitinib Shows Promise in Polycythemia Vera

Ruxolitinib, a JAK1/2 inhibitor approved by the FDA for the treatment of myelofibrosis, also has activity in another myeloproliferative neoplasm, polycythemia vera, according to...

Current Issue

February 2019, Volume 5, Issue 3

This issue features a look at the unique challenges of developing treatments for orphan diseases, more coverage of the 2018 ASH annual meeting, and more.